Table 2 Treatment response of bevacizumab plus irinotecan for patients with recurrent malignant glioma
Study | mPFS | PFS 6-month (%) | mOS | OS 6-month | Response rate (%) | Survival gain | Response gain |
|---|---|---|---|---|---|---|---|
Chen [15] | 2.4 | 9.5 | 8.5 | 61.9 | 38 | 4.23 | 21.37 |
Vredenburgh [16] | 5.5 | 46 | 9.6 | 77 | 57 | 5.07 | 42.18 |
Bokstein [17] | 4.2 | 25 | 7 | 55 | 47 | 0.73 | 31.02 |
Guiu [18] | NR | NR | NR | NR | 36 | -7.91 | 22.72 |
Ali [19] | 5.5 | 46.2 | 6.2 | 53.85 | 77 | 2.81 | 61.96 |
Desjardins [20] | 6.9 | 55 | 14.9 | 79 | 61 | 4.27 | 36.38 |
Kang [21] | 5.1 | 45.8 | 12.6 | 84 | 44 | 2.94 | 24.34 |
Poulsen [22] | 5 | 32.4 | 6.9 | NR | 28 | -0.65 | 8.24 |
Zuniga Cohort A [23] | 13.4 | 78.6 | NR | 85.7 | 86 | 12.6 | 61.49 |
Zuniga Cohort B [23] | 7.6 | 63.7 | 11.5 | 78 | 76 | 6.72 | 60.71 |
Friedman [24] | 5.6 | 50.5 | 8.7 | NR | 37.8 | 1.24 | 22.84 |